Formulation, Characterization and Stability Study of Encapsulated Anticancer drug in multilayered PEGylated Tumor targeting stealth Liposomes

Abstract

Present chemotherapy is low tumor selectivity with consequence undesirable side effects. Encapsulation of anticancer drug in to a pharmaceutical carrier such as liposome has been come with to overcome the difficulties developed by chemotherapeutic drugs. For this reason we formulated Capecitabine loaded stealth liposomes for anti-cancer therapy, in order to enhance bioavailability and to reduce dose frequency by reducing the toxicity and to target sites. Capecitabine is a prodrug of Fluorouracil (5 - FU), which is used to treat colorectal cancer, breast cancer and gastric cancer with improving drug concentrations through tumor-specific conversion to the active drug. PEGylated liposomes of capecitabine were prepared by thin film hydration Method from different combinations of phospholipids. Capectitabine stealth liposomes were prepared and evaluated for Particle size analysis, Zeta Potential, Entrapment Efficiency and drug release studies. Drug excipient compatibility was determined by FTIR. Percent entrapment efficiency of the formulations was found in the range of 54 % to 73%. The particle size analysis and zeta potential studies of Capecitabine stealth liposomes were analyzed by Malvern zetasizer ZX. Average size of Capecitabine loaded stealth liposomes was found to be in the range of 110-201 nm. Capecitabine loaded stealth liposomes have proved extended drug release and increased biological half life. After running ANOVA, the formulations of F3 CAP, F7 CAP were designated as the optimum formulations.